Tag: Phase V UMR
How to overcome the hidden challenges of new derivatives regulation :...
By Peter Rippon, CEO, OpenGamma.
New regulation introduced to mitigate the systemic risk associated with both cleared and uncleared OTC derivatives has also brought about additional...